메뉴 건너뛰기




Volumn 5, Issue , 2012, Pages 11-19

Insulin detemir for the treatment of obese patients with type 2 diabetes

Author keywords

Basal insulin; Body mass index; Detemir; Insulin analog; Satiety

Indexed keywords

ADIPONECTIN; ALBUMIN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HUMAN INSULIN; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT;

EID: 84857092826     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/dmso.s26980     Document Type: Article
Times cited : (19)

References (71)
  • 1
    • 84898689221 scopus 로고    scopus 로고
    • National Diabetes Information Clearinghouse. National Diabetes Statistics, Available from, Accessed October 6, 2011
    • National Diabetes Information Clearinghouse. National Diabetes Statistics, 2007. Available from: http://diabetes.niddk.nih.gov/dm/pubs/statistics/#allages. Accessed October 6, 2011.
    • (2007)
  • 3
    • 34247131681 scopus 로고    scopus 로고
    • The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: Comparison of data from two national surveys
    • Bays HE, Chapman RH, Grandy S. The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys. Int J Clin Pract. 2007;61(5): 737-747.
    • (2007) Int J Clin Pract , vol.61 , Issue.5 , pp. 737-747
    • Bays, H.E.1    Chapman, R.H.2    Grandy, S.3
  • 4
    • 0031848378 scopus 로고    scopus 로고
    • Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study
    • Wei M, Gaskill SP, Haffner SM, Stern MP. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care. 1998;21(7):1167-1172.
    • (1998) Diabetes Care , vol.21 , Issue.7 , pp. 1167-1172
    • Wei, M.1    Gaskill, S.P.2    Haffner, S.M.3    Stern, M.P.4
  • 5
    • 74349113610 scopus 로고    scopus 로고
    • Patient and treatment perspectives: Revisiting the link between type 2 diabetes, weight gain, and cardiovascular risk
    • AL. Patient and treatment perspectives: Revisiting the link between type 2 diabetes, weight gain, and cardiovascular risk. Cleve Clin J Med. 2009;76(Suppl 5):S20-S27.
    • (2009) Cleve Clin J Med , vol.76 , Issue.SUPPL. 5
  • 6
    • 77950654995 scopus 로고    scopus 로고
    • Comparing the actions of older and newer therapies on body weight: To what extent should these effects guide the selection of antidiabetic therapy?
    • Campbell IW. Comparing the actions of older and newer therapies on body weight: to what extent should these effects guide the selection of antidiabetic therapy? Int J Clin Pract. 2010;64(6):791-801.
    • (2010) Int J Clin Pract , vol.64 , Issue.6 , pp. 791-801
    • Campbell, I.W.1
  • 7
    • 35048841093 scopus 로고    scopus 로고
    • Insulin-associated weight gain in diabetes - causes, effects and coping strategies
    • Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes - causes, effects and coping strategies. Diabetes Obes Metab. 2007;9(6): 799-812.
    • (2007) Diabetes Obes Metab , vol.9 , Issue.6 , pp. 799-812
    • Russell-Jones, D.1    Khan, R.2
  • 8
    • 77954189321 scopus 로고    scopus 로고
    • The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus
    • Pi-Sunyer FX. The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus. Postgrad Med. 2009;121(5):94-107.
    • (2009) Postgrad Med , vol.121 , Issue.5 , pp. 94-107
    • Pi-Sunyer, F.X.1
  • 9
    • 77957690115 scopus 로고    scopus 로고
    • Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: Four-year results of the Look AHEAD trial
    • Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med. 2010;170(17):1566-1575.
    • (2010) Arch Intern Med , vol.170 , Issue.17 , pp. 1566-1575
    • Wing, R.R.1
  • 10
    • 0031904104 scopus 로고    scopus 로고
    • Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study
    • Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care. 1998;21(8):1288-1294.
    • (1998) Diabetes Care , vol.21 , Issue.8 , pp. 1288-1294
    • Hollander, P.A.1    Elbein, S.C.2    Hirsch, I.B.3
  • 11
    • 0037840403 scopus 로고    scopus 로고
    • Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: A randomized trial
    • Esposito K, Pontillo A, Di Palo C, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA. 2003;289(14):1799-1804.
    • (2003) JAMA , vol.289 , Issue.14 , pp. 1799-1804
    • Esposito, K.1    Pontillo, A.2    di Palo, C.3
  • 12
    • 0029977767 scopus 로고    scopus 로고
    • Exercise and weight control in sedentary overweight men: Effects on clinic and ambulatory blood pressure
    • Cox KL, Puddey IB, Morton AR, Burke V, Beilin LJ, McAleer M. Exercise and weight control in sedentary overweight men: effects on clinic and ambulatory blood pressure. J Hypertens. 1996;14(6):779-790.
    • (1996) J Hypertens , vol.14 , Issue.6 , pp. 779-790
    • Cox, K.L.1    Puddey, I.B.2    Morton, A.R.3    Burke, V.4    Beilin, L.J.5    McAleer, M.6
  • 14
    • 68349110805 scopus 로고    scopus 로고
    • Obesity, inflammation, and insulin resistance - a mini-review
    • Zeyda M, Stulnig TM. Obesity, inflammation, and insulin resistance - a mini-review. Gerontology. 2009;55(4):379-386.
    • (2009) Gerontology , vol.55 , Issue.4 , pp. 379-386
    • Zeyda, M.1    Stulnig, T.M.2
  • 15
    • 9844269567 scopus 로고    scopus 로고
    • Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus
    • Yki-Jarvinen H, Ryysy L, Kauppila M, et al. Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1997;82(12):4037-4043.
    • (1997) J Clin Endocrinol Metab , vol.82 , Issue.12 , pp. 4037-4043
    • Yki-Jarvinen, H.1    Ryysy, L.2    Kauppila, M.3
  • 16
    • 0035793139 scopus 로고    scopus 로고
    • Long-term weight loss and changes in blood pressure: Results of the Trials of Hypertension Prevention, phase II
    • Stevens VJ, Obarzanek E, Cook NR, et al. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med. 2001;134(1):1-11.
    • (2001) Ann Intern Med , vol.134 , Issue.1 , pp. 1-11
    • Stevens, V.J.1    Obarzanek, E.2    Cook, N.R.3
  • 17
    • 47549110641 scopus 로고    scopus 로고
    • Weight loss with a low- carbohydrate, Mediterranean, or low-fat diet
    • Shai I, Schwarzfuchs D, Henkin Y, et al. Weight loss with a low- carbohydrate, Mediterranean, or low-fat diet. N Engl J Med. 2008; 359(3):229-241.
    • (2008) N Engl J Med , vol.359 , Issue.3 , pp. 229-241
    • Shai, I.1    Schwarzfuchs, D.2    Henkin, Y.3
  • 18
    • 34249864128 scopus 로고    scopus 로고
    • Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: One-year results of the Look AHEAD trial
    • Pi-Sunyer X, Blackburn G, Brancati FL, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial. Diabetes Care. 2007;30(6): 1374-1383.
    • (2007) Diabetes Care , vol.30 , Issue.6 , pp. 1374-1383
    • Pi-Sunyer, X.1    Blackburn, G.2    Brancati, F.L.3
  • 19
    • 20444437249 scopus 로고    scopus 로고
    • Multi-targeted and aggressive treatment of patients with type 2 diabetes at high risk: What are we waiting for?
    • Gaede P, Pedersen O. Multi-targeted and aggressive treatment of patients with type 2 diabetes at high risk: what are we waiting for? Horm Metab Res. 2005;37(Suppl 1):76-82.
    • (2005) Horm Metab Res , vol.37 , Issue.SUPPL. 1 , pp. 76-82
    • Gaede, P.1    Pedersen, O.2
  • 20
    • 38949210220 scopus 로고    scopus 로고
    • Effect of a multifactorial intervention on mortality in type 2 diabetes
    • Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580-591.
    • (2008) N Engl J Med , vol.358 , Issue.6 , pp. 580-591
    • Gaede, P.1    Lund-Andersen, H.2    Parving, H.H.3    Pedersen, O.4
  • 21
    • 33750722123 scopus 로고    scopus 로고
    • Insulin treatment and the problem of weight gain in type 2 diabetes
    • Carver C. Insulin treatment and the problem of weight gain in type 2 diabetes. Diabetes Educ. 2006;32(6):910-917.
    • (2006) Diabetes Educ , vol.32 , Issue.6 , pp. 910-917
    • Carver, C.1
  • 22
    • 39049105019 scopus 로고    scopus 로고
    • A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes
    • Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia. 2008;51(3):408-416.
    • (2008) Diabetologia , vol.51 , Issue.3 , pp. 408-416
    • Rosenstock, J.1    Davies, M.2    Home, P.D.3    Larsen, J.4    Koenen, C.5    Schernthaner, G.6
  • 23
    • 77954255771 scopus 로고    scopus 로고
    • A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine oncedaily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs
    • Swinnen SG, Dain MP, Aronson R, et al. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine oncedaily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care. 2010;33(6):1176-1178.
    • (2010) Diabetes Care , vol.33 , Issue.6 , pp. 1176-1178
    • Swinnen, S.G.1    Dain, M.P.2    Aronson, R.3
  • 24
    • 33745027233 scopus 로고    scopus 로고
    • Cost-effectiveness of basal insulin from a US health system perspective: Comparative analyses of detemir, glargine, and NPH
    • Valentine WJ, Palmer AJ, Erny-Albrecht KM, et al. Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH. Adv Ther. 2006;23(2):191-207.
    • (2006) Adv Ther , vol.23 , Issue.2 , pp. 191-207
    • Valentine, W.J.1    Palmer, A.J.2    Erny-Albrecht, K.M.3
  • 25
    • 64649104158 scopus 로고    scopus 로고
    • From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus
    • DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773-795.
    • (2009) Diabetes , vol.58 , Issue.4 , pp. 773-795
    • Defronzo, R.A.1    Lecture, B.2
  • 26
    • 32144454714 scopus 로고    scopus 로고
    • Dispelling myths and removing barriers about insulin in type 2 diabetes
    • Meece J. Dispelling myths and removing barriers about insulin in type 2 diabetes. Diabetes Educ. 2006;32(1 Suppl):9S-18S.
    • (2006) Diabetes Educ , vol.32 , Issue.1 SUPPL.
    • Meece, J.1
  • 27
  • 28
    • 0033949070 scopus 로고    scopus 로고
    • Mechanisms for weight gain during blood glucose normalization
    • Laville M, Andreelli F. Mechanisms for weight gain during blood glucose normalization. Diabetes Metab. 2000;26(Suppl 3): 42-45.
    • (2000) Diabetes Metab , vol.26 , Issue.SUPPL. 3 , pp. 42-45
    • Laville, M.1    Andreelli, F.2
  • 29
    • 0024342099 scopus 로고
    • Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus
    • Groop L, Widen E, Franssila-Kallunki A, et al. Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1989;32(8):599-605.
    • (1989) Diabetologia , vol.32 , Issue.8 , pp. 599-605
    • Groop, L.1    Widen, E.2    Franssila-Kallunki, A.3
  • 30
    • 58149165212 scopus 로고    scopus 로고
    • Insulin analogs: Impact on treatment success, satisfaction, quality of life, and adherence
    • Hartman I. Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence. Clin Med Res. 2008;6(2):54-67.
    • (2008) Clin Med Res , vol.6 , Issue.2 , pp. 54-67
    • Hartman, I.1
  • 31
    • 2942574527 scopus 로고    scopus 로고
    • Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen
    • Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther. 2004;26(5):724-736.
    • (2004) Clin Ther , vol.26 , Issue.5 , pp. 724-736
    • Russell-Jones, D.1    Simpson, R.2    Hylleberg, B.3    Draeger, E.4    Bolinder, J.5
  • 32
    • 2342621441 scopus 로고    scopus 로고
    • Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: A randomized clinical trial
    • Home P, Bartley P, Russell-Jones D, et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care. 2004;27(5): 1081-1087.
    • (2004) Diabetes Care , vol.27 , Issue.5 , pp. 1081-1087
    • Home, P.1    Bartley, P.2    Russell-Jones, D.3
  • 33
    • 33746391488 scopus 로고    scopus 로고
    • A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes
    • Hermansen K, Davies M, Derezinski T, Ravn GM, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006;29(6):1269-1274.
    • (2006) Diabetes Care , vol.29 , Issue.6 , pp. 1269-1274
    • Hermansen, K.1    Davies, M.2    Derezinski, T.3    Ravn, G.M.4    Clauson, P.5    Home, P.6
  • 34
    • 63149103614 scopus 로고    scopus 로고
    • Intensive glycemic control and the prevention of cardiovascular events: Implications of the ACCORD, ADVANCE, and VA diabetes trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association
    • Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009;32(1):187-192.
    • (2009) Diabetes Care , vol.32 , Issue.1 , pp. 187-192
    • Skyler, J.S.1    Bergenstal, R.2    Bonow, R.O.3
  • 35
    • 9944261933 scopus 로고    scopus 로고
    • Insulin detemir: A review of its use in the management of type 1 and 2 diabetes mellitus
    • Chapman TM, Perry CM. Insulin detemir: a review of its use in the management of type 1 and 2 diabetes mellitus. Drugs. 2004;64(22): 2577-2595.
    • (2004) Drugs , vol.64 , Issue.22 , pp. 2577-2595
    • Chapman, T.M.1    Perry, C.M.2
  • 36
    • 33747799015 scopus 로고    scopus 로고
    • Insulin detemir in the treatment of type 1 and type 2 diabetes
    • Philips JC, Scheen A. Insulin detemir in the treatment of type 1 and type 2 diabetes. Vasc Health Risk Manag. 2006;2(3):277-283.
    • (2006) Vasc Health Risk Manag , vol.2 , Issue.3 , pp. 277-283
    • Philips, J.C.1    Scheen, A.2
  • 37
    • 60349128880 scopus 로고    scopus 로고
    • ® (insulin detemir [rDNA origin] injection), Princeton, NJ: Novo Nordisk Inc, Nov
    • ® (insulin detemir [rDNA origin] injection). Prescribing information. Princeton, NJ: Novo Nordisk Inc; Nov 2010.
    • (2010) Prescribing Information
  • 38
    • 4344701890 scopus 로고    scopus 로고
    • The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin
    • Havelund S, Plum A, Ribel U, et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res. 2004;21(8):1498-1504.
    • (2004) Pharm Res , vol.21 , Issue.8 , pp. 1498-1504
    • Havelund, S.1    Plum, A.2    Ribel, U.3
  • 39
    • 58149199751 scopus 로고    scopus 로고
    • Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: A double-blind, randomized, crossover study
    • King AB. Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study. Diabetes Obes Metab. 2009;11(1):69-71.
    • (2009) Diabetes Obes Metab , vol.11 , Issue.1 , pp. 69-71
    • King, A.B.1
  • 40
    • 33645967817 scopus 로고    scopus 로고
    • Insulin detemir under steady-state conditions: No accumulation and constant metabolic effect over time with twice daily administration in subjects with type 1 diabetes
    • Bott S, Tusek C, Jacobsen LV, et al. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with type 1 diabetes. Diabet Med. 2006;23:522-528.
    • (2006) Diabet Med , vol.23 , pp. 522-528
    • Bott, S.1    Tusek, C.2    Jacobsen, L.V.3
  • 41
    • 20944432717 scopus 로고    scopus 로고
    • A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir
    • Plank J, Bodenlenz M, Sinner F, et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care. 2005;28(5):1107-1112.
    • (2005) Diabetes Care , vol.28 , Issue.5 , pp. 1107-1112
    • Plank, J.1    Bodenlenz, M.2    Sinner, F.3
  • 42
    • 33947644300 scopus 로고    scopus 로고
    • Albuminbound basal insulin analogues (insulin detemir and NN344): Comparable time-action profiles but less variability than insulin glargine in type 2 diabetes
    • Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T. Albuminbound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab. 2007;9(3):290-299.
    • (2007) Diabetes Obes Metab , vol.9 , Issue.3 , pp. 290-299
    • Klein, O.1    Lynge, J.2    Endahl, L.3    Damholt, B.4    Nosek, L.5    Heise, T.6
  • 43
    • 34547908855 scopus 로고    scopus 로고
    • Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies
    • Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab. 2007;9(5):648-659.
    • (2007) Diabetes Obes Metab , vol.9 , Issue.5 , pp. 648-659
    • Heise, T.1    Pieber, T.R.2
  • 44
    • 2542576404 scopus 로고    scopus 로고
    • Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes
    • Heise T, Nosek L, Ronn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53(6): 1614-1620.
    • (2004) Diabetes , vol.53 , Issue.6 , pp. 1614-1620
    • Heise, T.1    Nosek, L.2    Ronn, B.B.3
  • 45
    • 55949103510 scopus 로고    scopus 로고
    • Switching from NPH insulin to once-daily insulin detemir in basal-bolus-treated patients with diabetes mellitus: Data from the European cohort of the PREDICTIVE study
    • Sreenan S, Virkamaki A, Zhang K, Hansen JB. Switching from NPH insulin to once-daily insulin detemir in basal-bolus-treated patients with diabetes mellitus: data from the European cohort of the PREDICTIVE study. Int J Clin Pract. 2008;62(12):1971-1980.
    • (2008) Int J Clin Pract , vol.62 , Issue.12 , pp. 1971-1980
    • Sreenan, S.1    Virkamaki, A.2    Zhang, K.3    Hansen, J.B.4
  • 46
    • 48249139906 scopus 로고    scopus 로고
    • Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients - the PREDICTIVE™ BMI clinical trial
    • Fajardo Montanana C, Hernandez Herrero C, Rivas Fernandez M. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients - the PREDICTIVE™ BMI clinical trial. Diabet Med. 2008;25(8):916-923.
    • (2008) Diabet Med , vol.25 , Issue.8 , pp. 916-923
    • Fajardo, M.C.1    Hernandez, H.C.2    Rivas, F.M.3
  • 47
    • 33947302393 scopus 로고    scopus 로고
    • Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index
    • Raslova K, Tamer SC, Clauson P, Karl D. Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. Clin Drug Invest. 2007;27(4):279-285.
    • (2007) Clin Drug Invest , vol.27 , Issue.4 , pp. 279-285
    • Raslova, K.1    Tamer, S.C.2    Clauson, P.3    Karl, D.4
  • 48
    • 33845236398 scopus 로고    scopus 로고
    • Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes
    • Philis-Tsimikas A, Charpentier G, Clauson P, Martinez Ravn G, Roberts VL, Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther. 2006;28(10): 1569-1581.
    • (2006) Clin Ther , vol.28 , Issue.10 , pp. 1569-1581
    • Philis-Tsimikas, A.1    Charpentier, G.2    Clauson, P.3    Martinez, R.G.4    Roberts, V.L.5    Thorsteinsson, B.6
  • 49
    • 57649230070 scopus 로고    scopus 로고
    • A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes
    • Hollander P, Cooper J, Bregnhoj J, Pedersen CB. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther. 2008;30(11):1976-1987.
    • (2008) Clin Ther , vol.30 , Issue.11 , pp. 1976-1987
    • Hollander, P.1    Cooper, J.2    Bregnhoj, J.3    Pedersen, C.B.4
  • 50
    • 70350605350 scopus 로고    scopus 로고
    • Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes
    • Raskin P, Gylvin T, Weng W, Chaykin L. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes Metab Res Rev. 2009;25(6):542-548.
    • (2009) Diabetes Metab Res Rev , vol.25 , Issue.6 , pp. 542-548
    • Raskin, P.1    Gylvin, T.2    Weng, W.3    Chaykin, L.4
  • 51
    • 48449094712 scopus 로고    scopus 로고
    • Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type-2 diabetes
    • Fakhoury W, Lockhart I, Kotchie RW, Aagren M, Lereun C. Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type-2 diabetes. Pharmacology. 2008;82(2):156-163.
    • (2008) Pharmacology , vol.82 , Issue.2 , pp. 156-163
    • Fakhoury, W.1    Lockhart, I.2    Kotchie, R.W.3    Aagren, M.4    Lereun, C.5
  • 52
    • 33751361649 scopus 로고    scopus 로고
    • Glycemic control with insulin glargine as part of an ethnically diverse, community-based diabetes management program
    • Philis-Tsimikas A, Zhang Q, Walker C. Glycemic control with insulin glargine as part of an ethnically diverse, community-based diabetes management program. Am J Ther. 2006;13(6):466-472.
    • (2006) Am J Ther , vol.13 , Issue.6 , pp. 466-472
    • Philis-Tsimikas, A.1    Zhang, Q.2    Walker, C.3
  • 53
    • 65549131199 scopus 로고    scopus 로고
    • Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: An assessment of two different fasting plasma glucose targets - the TITRATE study
    • Blonde L, Merilainen M, Karwe V, Raskin P. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study. Diabetes Obes Metab. 2009;11(6):623-631.
    • (2009) Diabetes Obes Metab , vol.11 , Issue.6 , pp. 623-631
    • Blonde, L.1    Merilainen, M.2    Karwe, V.3    Raskin, P.4
  • 54
    • 35748933179 scopus 로고    scopus 로고
    • Lower risk of hypoglycemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: A pooled analysis of phase III trials
    • Garber AJ, Clauson P, Pedersen CB, Kolendorf K. Lower risk of hypoglycemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase III trials. J Am Geriatr Soc. 2007;55(11):1735-1740.
    • (2007) J Am Geriatr Soc , vol.55 , Issue.11 , pp. 1735-1740
    • Garber, A.J.1    Clauson, P.2    Pedersen, C.B.3    Kolendorf, K.4
  • 55
    • 77955031968 scopus 로고    scopus 로고
    • Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine
    • Home PD, Fritsche A, Schinzel S, Massi-Benedetti M. Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine. Diabetes Obes Metab. 2010;12(9):772-779.
    • (2010) Diabetes Obes Metab , vol.12 , Issue.9 , pp. 772-779
    • Home, P.D.1    Fritsche, A.2    Schinzel, S.3    Massi-Benedetti, M.4
  • 56
    • 33947695694 scopus 로고    scopus 로고
    • Does insulin detemir have a role in reducing risk of insulin-associated weight gain?
    • Hermansen K, Davies M. Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diabetes Obes Metab. 2007;9(3): 209-217.
    • (2007) Diabetes Obes Metab , vol.9 , Issue.3 , pp. 209-217
    • Hermansen, K.1    Davies, M.2
  • 57
    • 61449244692 scopus 로고    scopus 로고
    • Efficacy and safety of insulin analogues for the management of diabetes mellitus: A meta-analysis
    • Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ. 2009;180(4):385-397.
    • (2009) CMAJ , vol.180 , Issue.4 , pp. 385-397
    • Singh, S.R.1    Ahmad, F.2    Lal, A.3    Yu, C.4    Bai, Z.5    Bennett, H.6
  • 58
    • 50049096963 scopus 로고    scopus 로고
    • Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia
    • Davies MJ, Derezinski T, Pedersen CB, Clauson P. Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. Diabetes Technol Ther. 2008;10(4):273-277.
    • (2008) Diabetes Technol Ther , vol.10 , Issue.4 , pp. 273-277
    • Davies, M.J.1    Derezinski, T.2    Pedersen, C.B.3    Clauson, P.4
  • 59
    • 70350143228 scopus 로고    scopus 로고
    • Insulin detemir causes increased symptom awareness during hypoglycaemia compared to human insulin
    • Tschritter O, Schafer SA, Klett J, et al. Insulin detemir causes increased symptom awareness during hypoglycaemia compared to human insulin. Diabetes Obes Metab. 2009;11(11):1017-1026.
    • (2009) Diabetes Obes Metab , vol.11 , Issue.11 , pp. 1017-1026
    • Tschritter, O.1    Schafer, S.A.2    Klett, J.3
  • 60
    • 16844368165 scopus 로고    scopus 로고
    • Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp
    • Hordern SV, Wright JE, Umpleby AM, Shojaee-Moradie F, Amiss J, Russell-Jones DL. Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp. Diabetologia. 2005;48:420-426.
    • (2005) Diabetologia , vol.48 , pp. 420-426
    • Hordern, S.V.1    Wright, J.E.2    Umpleby, A.M.3    Shojaee-Moradie, F.4    Amiss, J.5    Russell-Jones, D.L.6
  • 62
    • 77951150702 scopus 로고    scopus 로고
    • Euglycemic infusion of insulin detemir compared to human insulin appears to increase direct current brain potential response and reduces food intake while inducing similar systemic effects
    • Hallschmid M, Jauch-Chara K, Korn O, et al. Euglycemic infusion of insulin detemir compared to human insulin appears to increase direct current brain potential response and reduces food intake while inducing similar systemic effects. Diabetes. 2010;59(4):1101-1107.
    • (2010) Diabetes , vol.59 , Issue.4 , pp. 1101-1107
    • Hallschmid, M.1    Jauch-Chara, K.2    Korn, O.3
  • 63
    • 78049457381 scopus 로고    scopus 로고
    • Insulin detemir is not transported across the blood-brain barrier
    • Banks WA, Morley JE, Lynch JL, Lynch KM, Mooradian AD. Insulin detemir is not transported across the blood-brain barrier. Peptides. 2010;31(12):2284-2288.
    • (2010) Peptides , vol.31 , Issue.12 , pp. 2284-2288
    • Banks, W.A.1    Morley, J.E.2    Lynch, J.L.3    Lynch, K.M.4    Mooradian, A.D.5
  • 64
    • 73549099979 scopus 로고    scopus 로고
    • Evaluation of the lack of anorectic effect of intracerebroventricular insulin in rats
    • Jessen L, Clegg DJ, Bouman SD. Evaluation of the lack of anorectic effect of intracerebroventricular insulin in rats. Am J Physiol Regul Integr Comp Physiol. 2010;298(1):R43-R50.
    • (2010) Am J Physiol Regul Integr Comp Physiol , vol.298 , Issue.1
    • Jessen, L.1    Clegg, D.J.2    Bouman, S.D.3
  • 65
    • 84857079496 scopus 로고    scopus 로고
    • Insulin detemir reduces gain in bodyweight and fat mass in ZDF rats when compared with both NPH and insulin glargine
    • abstr 975
    • Fledelius C, Damgaard J, Vinterby A, Ribel U, Petersen JS, Sturis J. Insulin detemir reduces gain in bodyweight and fat mass in ZDF rats when compared with both NPH and insulin glargine. Diabetologia. 2008;51(Suppl 1):S392 (abstr 975).
    • (2008) Diabetologia , vol.51 , Issue.SUPPL. 1
    • Fledelius, C.1    Damgaard, J.2    Vinterby, A.3    Ribel, U.4    Petersen, J.S.5    Sturis, J.6
  • 66
    • 84898699729 scopus 로고    scopus 로고
    • The weight sparing effect of insulin detemir is associated with increased adiponectin levels and decreased adiposity in the diabetic ZDF rat
    • (abstr 727
    • Fledelius C, Olsen GS, Jensen AB, et al. The weight sparing effect of insulin detemir is associated with increased adiponectin levels and decreased adiposity in the diabetic ZDF rat. Diabetologia. 2009; 52(Suppl 1):S285. (abstr 727).
    • (2009) Diabetologia , vol.52 , Issue.SUPPL. 1
    • Fledelius, C.1    Olsen, G.S.2    Jensen, A.B.3
  • 67
    • 1942534687 scopus 로고    scopus 로고
    • Adiponectin and its role in the obesity-induced insulin resistance and related complications
    • Haluzik M, Parizkova J, Haluzik MM. Adiponectin and its role in the obesity-induced insulin resistance and related complications. Physiol Res. 2004;53(2):123-129.
    • (2004) Physiol Res , vol.53 , Issue.2 , pp. 123-129
    • Haluzik, M.1    Parizkova, J.2    Haluzik, M.M.3
  • 68
    • 4444344507 scopus 로고    scopus 로고
    • Lipids and glucose in type 2 diabetes: What is the cause and effect?
    • Boden G, Laakso M. Lipids and glucose in type 2 diabetes: what is the cause and effect? Diabetes Care. 2004;27(9):2253-2259.
    • (2004) Diabetes Care , vol.27 , Issue.9 , pp. 2253-2259
    • Boden, G.1    Laakso, M.2
  • 69
    • 79960297902 scopus 로고    scopus 로고
    • The relationship of adiponectin/leptin ratio with homeostasis model assessment insulin resistance index and metabolic syndrome in apparently healthy korean male adults
    • Jung CH, Rhee EJ, Choi JH, et al. The relationship of adiponectin/leptin ratio with homeostasis model assessment insulin resistance index and metabolic syndrome in apparently healthy korean male adults. Korean Diabetes J. 2010;34(4):237-243.
    • (2010) Korean Diabetes J , vol.34 , Issue.4 , pp. 237-243
    • Jung, C.H.1    Rhee, E.J.2    Choi, J.H.3
  • 70
    • 56249143771 scopus 로고    scopus 로고
    • Effect of insulin detemir, compared to human insulin, on 3T3-L1 adipogenesis
    • Bohm A, Staiger H, Hennige AM, Haas C, Machicao F, Haring HU. Effect of insulin detemir, compared to human insulin, on 3T3-L1 adipogenesis. Regul Pept. 2008;151(1-3):160-163.
    • (2008) Regul Pept , vol.151 , Issue.1-3 , pp. 160-163
    • Bohm, A.1    Staiger, H.2    Hennige, A.M.3    Haas, C.4    Machicao, F.5    Haring, H.U.6
  • 71
    • 38449115454 scopus 로고    scopus 로고
    • Actions of insulin beyond glycemic control: A perspective on insulin detemir
    • Tibaldi J. Actions of insulin beyond glycemic control: a perspective on insulin detemir. Adv Ther. 2007;24(4):868-882.
    • (2007) Adv Ther , vol.24 , Issue.4 , pp. 868-882
    • Tibaldi, J.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.